Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CDC7 | O00311 | 1/20 | 0.48 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 1/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29837473 | 0.87 | TSHR (0.60) | TSHRNUDT1TP53CASP1CDC7 | |
| SCHEMBL3515887 | 0.87 | TSHR (0.60) | TSHRNUDT1TP53CASP1CDC7 | |
| SCHEMBL907851 | 0.86 | SIRT3 (0.58) | TSHRNUDT1TP53CASP1CDC7 | |
| SCHEMBL29570949 | 0.86 | SIRT3 (0.58) | TSHRNUDT1TP53CASP1CDC7 | |
| SCHEMBL13758656 | 0.84 | TSHR (0.52) | TSHRNUDT1TP53CASP1CDC7 | |
| SCHEMBL2568123 | 0.84 | CA12 (0.56) | TSHRNUDT1TP53CASP1CDC7 | |
| Ethane SCHEMBL28930003 | 0.84 | SIRT3 (0.56) | TSHRNUDT1TP53CASP1CDC7 | |
| SCHEMBL12447815 | 0.84 | TSHR (0.52) | TSHRNUDT1TP53CASP1CDC7 | |
| SCHEMBL14398405 | 0.83 | TSHR (0.50) | TSHRNUDT1TP53CASP1CDC7 | |
| Iodomethane SCHEMBL10841815 | 0.83 | SIRT3 (0.54) | TSHRNUDT1TP53CASP1CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217964-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. | 2024-07-04 | — | — | US | disclosed |
| CN-116034107-A | Quinuclidinone analogs as anticancer agents | 新波制药有限公司 | 2023-04-28 | — | — | CN | disclosed |
| US-20230089530-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. | 2023-03-23 | — | — | US | disclosed |
| EP-4100407-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | Newave Pharmaceutical Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022204109-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2021158948-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-05-10 | — | — | US | disclosed |
| CN-103237803-B | Triazolopyridine compounds | HOFFMAN-LA ROCHE LTD. (CH) | 2016-04-13 | — | — | CN | disclosed |
| CN-104684913-A | Tris(hetero)arylpyrazoles and use thereof | AICURIS GMBH & CO KG | 2015-06-03 | — | — | CN | disclosed |
| US-6777414-B1 | INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| EP-1404672-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030100567-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003000687-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-1180514-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
| EP-0509769-B1 | Heterocyclic amides having HLE inhibiting activity | ZENECA LTD (GB) | 1996-09-11 | — | — | EP | disclosed |
| US-5521179-A | Heterocyclic amides | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
| EP-0284174-B1 | THERAPEUTIC PREPARATIONS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-29 | — | — | EP | disclosed |
| EP-0284174-A1 | Therapeutic preparations | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089530-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NQO2, CNKSR1, NQO1 | TSHR 2740/4885NUDT1 491/4885TP53 58/4885 |
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | KRAS, NRAS, HRAS | TSHR 2524/4885NUDT1 1171/4885TP53 22/4885 |
| US-20240217964-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NQO2, PRMT1, PRMT7 | TSHR 1187/4885NUDT1 392/4885TP53 107/4885 |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | TSHR 2663/4885NUDT1 1446/4885TP53 20/4885 |
| US-20030100567-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | TSHR 1987/4885NUDT1 3691/4885TP53 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.